GTF2H5: A Promising Protein for Drug Targets and Biomarkers (G404672)

Target Name: GTF2H5

NCBI ID: G404672

GTF2H5

GTF2H5: A Promising Protein for Drug Targets and Biomarkers

GTF2H5 (TTD3), a protein encoded by the gene GTF2H5, is a member of the GTF2H family of genes, which are known to play a crucial role in the development and progression of various diseases, including cancer. GTF2H5 is a 21-kDa transmembrane protein that is expressed in a variety of tissues, including brain, heart, and muscle. Its function in these cells is not well understood, but it is known to be involved in several cellular processes, including cell signaling, cell adhesion, and cell survival.

One of the most promising aspects of GTF2H5 is its potential as a drug target. The TTD3 gene has been identified as a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The reason for its potential as a drug target is its unique structure and the various functions it is involved in.

GTF2H5 is a transmembrane protein that is involved in several cellular processes. It is known to be involved in cell signaling, as it has been shown to be a target for several signaling pathways, including TGF-β, NF-kappa-B, and PI3K. GTF2H5 is also involved in cell adhesion, as it is a co-factor for the protein Focal Adhesion molecule (FAM), which is involved in cell-cell adhesion. Additionally, GTF2H5 is known to be involved in cell survival, as it has been shown to play a role in the regulation of cell apoptosis.

The potential benefits of targeting GTF2H5 are numerous. For example, it is a potential target for several diseases that are currently treated with drugs that are known to be effective in treating those diseases. For example, GTF2H5 is a potential target for cancer, as it has been shown to be involved in the development and progression of several types of cancer. Additionally, GTF2H5 is a potential target for neurodegenerative diseases, as it has been shown to be involved in the development and progression of several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target, GTF2H5 is also a potential biomarker for several diseases. For example, it has been shown to be a potential biomarker for cancer, as it has been shown to be expressed in the brains of patients with cancer. Additionally, GTF2H5 has been shown to be a potential biomarker for neurodegenerative diseases, as it has been shown to be expressed in the brains of patients with neurodegenerative diseases.

In conclusion, GTF2H5 is a unique and promising protein that is involved in several cellular processes. Its potential as a drug target and biomarker make it an attractive target for researchers to investigate further. Further studies are needed to fully understand its functions and potential as a drug and biomarker.

Protein Name: General Transcription Factor IIH Subunit 5

Functions: Component of the general transcription and DNA repair factor IIH (TFIIH) core complex, which is involved in general and transcription-coupled nucleotide excision repair (NER) of damaged DNA and, when complexed to CAK, in RNA transcription by RNA polymerase II. In NER, TFIIH acts by opening DNA around the lesion to allow the excision of the damaged oligonucleotide and its replacement by a new DNA fragment. In transcription, TFIIH has an essential role in transcription initiation. When the pre-initiation complex (PIC) has been established, TFIIH is required for promoter opening and promoter escape. Phosphorylation of the C-terminal tail (CTD) of the largest subunit of RNA polymerase II by the kinase module CAK controls the initiation of transcription. Necessary for the stability of the TFIIH complex and for the presence of normal levels of TFIIH in the cell

The "GTF2H5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GTF2H5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets